Singapore approves Aevice Well being’s wearable stethoscope for respiratory monitoring

Aevice Well being has introduced that its flagship medical machine, a wearable stethoscope for respiratory well being monitoring, has been accredited by Singapore’s Well being Sciences Authority. 

The AI-powered wearable stethoscope AeviceMD, which is worn on the chest, constantly detects and information irregular breath sounds, equivalent to wheezing, and screens important indicators together with coronary heart price and respiratory price. 

Based mostly on a press assertion, the monitoring machine system has been accredited to be used in folks aged three and above and in each medical and residential settings. 

WHY IT MATTERS

Singapore has one of many highest bronchial asthma and COPD prevalences on the earth. Bronchial asthma impacts round 5% of adults and 20% of kids within the nation whereas COPD is among the 10 main illness killers. 

With its distant well being monitoring expertise, Aevice Well being goals to assist cut back ED displays and readmissions amongst sufferers coping with these persistent respiratory ailments.  By offering well being professionals with an outline of a affected person’s lung well being, AeviceMD helps the early detection of potential exacerbations.

In accordance with the corporate, it’s going to use its HSA approval as a springboard to broaden the attain of its expertise to populations with excessive circumstances of respiratory ailments. 

“We’re excited to leverage Singapore’s strategic presence in Asia as a medical hub to deliver this novel expertise into new markets the place there’s a excessive prevalence of respiratory ailments,” Aevice Well being CEO Adrian Ang shared.

THE LARGER TREND

The market approval comes two years since Aevice Well being first performed a clinical trial of AeviceMD with the Nationwide College Well being System to research its use circumstances in paediatric sufferers with respiration difficulties.  

Apart from Singapore, the machine has additionally been introduced in Japan utilizing the $2 million proceeds from its pre-Sequence A funding spherical in 2021.